Teva (NYSE: TEVA) interim CLO discloses stock options and RSU grants

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. filed an initial ownership report for interim Chief Legal Officer Brian Savage, detailing his existing equity awards and share holdings. The filing lists direct holdings of stock options, multiple tranches of restricted share units with specified vesting schedules through 2029, and ordinary shares that may be represented by American Depositary Shares. It does not record any new purchases or sales, but simply discloses current positions and how and when they vest into ordinary shares or cash.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Savage Brian

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/11/2026

3. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Legal Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	739	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(2)	03/17/2026	Ordinary Shares(1)	2,253	$53.5	D
Stock Options (right to buy)	(3)	03/03/2027	Ordinary Shares(1)	4,503	$34.7	D
Restricted Share Units	(4)	(4)	Ordinary Shares(1)	18,967	(5)	D
Restricted Share Units	(6)	(6)	Ordinary Shares(1)	13,844	(5)	D
Restricted Share Units	(7)	(7)	Ordinary Shares(1)	15,066	(5)	D
Restricted Share Units	(8)	(8)	Ordinary Shares(1)	14,320	(5)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Stock options were granted on March 17, 2016, with 563 vested on each of March 17, 2017, March 17, 2018 and March 17, 2019, and 564 vested on March 17, 2020.

3. Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.

4. Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vesting on March 4, 2026.

5. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

6. Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024 and March 3, 2025, and 3,461 vesting on each of March 3, 2026 and March 3, 2027.

7. Restricted share units were granted on March 4, 2024, with 3,766 vested on March 4, 2025, 3,766 vesting on each of March 4, 2026 and March 4, 2027, and 3,768 vesting on March 4, 2028.

8. Restricted share units were granted on March 5, 2025, with 3,580 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 for TEVA disclose about Brian Savage’s holdings?

The Form 3 discloses Brian Savage’s existing equity interests, including stock options, restricted share units, and ordinary shares. It provides detailed vesting schedules for past grants and confirms all positions are held as direct ownership in Teva Pharmaceutical Industries Ltd.

Are there any stock option grants reported for TEVA’s Brian Savage?

Yes. Stock options were granted on March 17, 2016 and March 3, 2017, with portions vesting annually from 2017 through 2021. The Form 3 shows the total stock options held following these grants as part of his current equity position.

What restricted share unit grants are reported for TEVA interim CLO Brian Savage?

The filing reports restricted share units granted on March 4, 2022, March 3, 2023, March 4, 2024, and March 5, 2025. These RSUs vest in annual installments from 2023 through 2029, creating a multi‑year schedule of potential share or cash settlements.

How do the restricted share units in the TEVA Form 3 settle at vesting?

Each restricted share unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. This flexibility is specifically described in the footnotes to the Form 3 filing.

How are TEVA ordinary shares related to American Depositary Shares in this filing?

The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share. This clarifies how U.S. investors might hold equivalent interests in the company’s ordinary equity.

Does TEVA’s Form 3 show any insider buying or selling by Brian Savage?

No. The Form 3 is an initial ownership statement listing existing stock options, restricted share units, and ordinary shares. It does not report any new purchase or sale transactions, only the current amounts held after prior grants and vesting.